NasdaqGS:CMPSBiotechs
Is COMPASS Pathways (CMPS) Undervalued As Phase 3 Progress And FDA Review Advance?
COMPASS Pathways (NasdaqGS:CMPS) is back in focus after reporting 26 week Phase 3 COMP006 data for its COMP360 psilocybin candidate in treatment resistant depression, alongside supportive regulatory progress and new PTSD analysis.
See our latest analysis for COMPASS Pathways.
Despite the latest positive trial readout, COMPASS Pathways' share price has been volatile, with a 1 day share price return that declined 6.61% and a 7 day share price return that declined 8.60%. However, the 90 day...